Click here to read the Cover Story, “Specialists navigate changing, challenging landscape of geographic atrophy management.”Geographic atrophy management could benefit greatly from the combination of novel therapies and AI-driven imaging technology.However, while our U.S. colleagues have FDA-approved complement inhibitors available but no tools, in Europe, we have approved … [Read more...] about Could AI improve available treatments for geographic atrophy?
News
VIS-101 shows safety, rapid efficacy in wet AMD
Editor’s note: This is a developing news story. Please check back soon for updates.A dual VEGF-A and angiopoietin-2 inhibitor provided fast, durable treatment for wet age-related macular degeneration in a phase 2a study, according to a press release from NovaBridge.NovaBridge and subsidiary Visara announced topline results from the phase 2a study of VIS-101 for the treatment of … [Read more...] about VIS-101 shows safety, rapid efficacy in wet AMD
Severe Sleep Apnea May Be Associated With Damage to the Limbal Epithelium
Patients with prolonged hypoxia due to severe obstructive sleep apnea were found to have a significantly thinner limbal epithelium compared with patients with no sleep apnea or milder disease. … [Read more...] about Severe Sleep Apnea May Be Associated With Damage to the Limbal Epithelium
Qlaris Bio appoints new CEO Fred Guerard
Qlaris Bio appointed Fred Guerard, PharmD, as its president and CEO, according to a press release.The company is entering phase 3 development of QLS-111, a novel eye drop for lowering IOP in patients with open-angle glaucoma and ocular hypertension (OHT). In a statement to Healio, Guerard said he is coming to the company at an important time, with “promising results” coming out … [Read more...] about Qlaris Bio appoints new CEO Fred Guerard
Specialists navigate challenging landscape of geographic atrophy
The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and brought new changes and challenges in clinical practice, workflow and capacity.The FDA approved complement inhibitors Syfovre (pegcetacoplan injection, Apellis) and Izervay (avacincaptad pegol intravitreal solution, Astellas) in 2023, and since then, the … [Read more...] about Specialists navigate challenging landscape of geographic atrophy